EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Initial treatment for FIGO 2018 stage IIIC cervical cancer based on histological type: A 14‐year multicenter study

Yanna Ye iD, Guochao Zhang, Zhiqiang Li, Biliang Chen, Hongwei Zhao, Ying Yang, Li Wang, Jilong Yao, Xiaolin Chen, Yahong Huang, Jinghe Lang, Ping Liu und 1 weitere

Cancer Medicine · 2023

DOI: 10.1002/cam4.6586 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, 2023. Verfasst von Yanna Ye und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Midwifery, Faculty of Health, Dongguan Polytechnic, Dongguan, China. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Carcinoma, Squamous Cell, Carcinoma, Adenosquamous, Adenocarcinoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To compare the oncological outcomes of radical chemotherapy (R‐CT), abdominal radical hysterectomy (ARH), and neoadjuvant chemotherapy and radical surgery (NACT) for International Federation of Gynecology and Obstetrics (FIGO) 2018 stage IIIC cervical cancer, according to histological types: squamous cell carcinoma (SCC) and adenocarcinoma (AC)/adenosquamous cell carcinoma (ASC).

Methods

A comparison of 5‐year overall survival (OS) and disease‐free survival (DFS) was performed for the SCC and AC/ASC subgroups for the three initial treatments, assessed using Kaplan–Meier and Cox proportional hazards regression analysis and validated using propensity score matching (PSM).

Results

The study included 4086 patients: R‐CT, n = 1913; ARH, n = 1529; and NACT, n = 644. AC/ASC had a lower survival rate (63.7%) than SCC (73.6%) and a higher recurrence and mortality rate (36.3% and 26.4%, respectively). The 5‐year OS and DFS rates were different in the SCC group for R‐CT, ARH, and NACT (OS: 69.8% vs. 80.8% vs. 73.0%, p < 0.001; DFS: 66.7% vs. 70.7% vs. 56.4%, p < 0.001), also in the AC/ASC group (OS: 46.1% vs. 70.6% vs. 55.6%, p < 0.001; DFS: 42.7% vs. 64.6% vs. 40.8%, p < 0.001). As for initial treatment, survival outcomes were worse for AC/ASC treated with R‐CT and ARH than for SCC (both p < 0.05), with no group differences between the two treated with NACT.

Conclusion

Initial treatment influences oncological prognosis for patients with FIGO 2018 stage IIIC cervical cancer. ARH is an alternative treatment for stage IIIC cervical SCC and AC/ASC, and NACT needs to be chosen with caution, moreover, R‐CT for AC/ASC requires careful selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsCarcinoma, Squamous CellCarcinoma, AdenosquamousAdenocarcinomaFemaleHumansRetrospective StudiesPrognosisNeoplasm StagingHysterectomy

Stichwörter der Autor:innen

adenocarcinoma/adenosquamous cell carcinomacervical cancercervical cancer treatmentsquamous cell carcinomastage IIIC cervical cancer

Autor:innen und Institutionen

  • Department of Midwifery, Faculty of Health, Dongguan Polytechnic, Dongguan, China.
  • Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Department of General Surgery, China-Japan Friendship Hospital, Beijing, China.
  • Department of Obstetrics and Gynecology, Xijing Hospital of Airforce Medical University, Xian, China.
  • Department of Gynecologic Oncology, Shanxi Provincial Cancer Hospital, Taiyuan, China.
  • Department of Obstetrics and Gynecology, Xinqiao Hospital, Army Medical University, Chongqing, China.

ORCID-Profile: Yanna Ye, Chunlin Chen

Zitieren

APA

Ye, Y., Zhang, G., Li, Z., Chen, B., Zhao, H., Yang, Y., Wang, L., Yao, J., Chen, X., Huang, Y., Lang, J., Liu, P., & Chen, C. (2023). Initial treatment for FIGO 2018 stage IIIC cervical cancer based on histological type: A 14‐year multicenter study. Cancer Medicine. https://doi.org/10.1002/cam4.6586

Vancouver

Ye Y, Zhang G, Li Z, Chen B, Zhao H, Yang Y, et al. Initial treatment for FIGO 2018 stage IIIC cervical cancer based on histological type: A 14‐year multicenter study. Cancer Medicine. 2023. doi:10.1002/cam4.6586

BibTeX
@article{Ye2023,
  author = {Ye, Yanna and Zhang, Guochao and Li, Zhiqiang and Chen, Biliang and Zhao, Hongwei and Yang, Ying and Wang, Li and Yao, Jilong and Chen, Xiaolin and Huang, Yahong and Lang, Jinghe and Liu, Ping and Chen, Chunlin},
  title = {Initial treatment for FIGO 2018 stage IIIC cervical cancer based on histological type: A 14‐year multicenter study},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6586}
}
Kostenlos starten →